Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26

About this update from Altimmune, Inc.

[{"type":"image","alt":"Altimmune, Inc","displaySize":"","headline":null,"caption":"Altimmune, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":82,"url":"https://media.zenfs.com/en/globenewswire.com/767e25bad8979b96701d6a099286a009"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gY.Kxe7ML79dI0xW5370RA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTExNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/767e25bad8979b96701d6a099286a009","width":150,"height":82}},"lazy":false},{"type":"text","content":"Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T.","length":76,"tagName":"p"},{"type":"text","content":"GAITHERSBURG, Md., June 25, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, will host an investor webcast on Thursday, June 26, 2025 at 8:30 am E.T. to present topline 24 week data from its IMPACT Phase 2b trial evaluating pemvidutide in the treatment of patients with metabolic dysfunction-associated steatohepatitis (MASH).","length":465,"tagName":"p"},{"type":"text","content":"Conference Call InformationThe Company will host a conference call and webcast at 8:30 am E.T. on June 26, 2025. The call will include remarks from Altimmune management and Dr. Mazen Noureddin, Professor of Medicine at the Houston Methodist Hospital and Co-Chairman of the Board for Summit Clinical Research and Pinnacle Clinical Research. Following the conclusion of the call, the webcast will be available for replay on the Investor Relations page of the Company’s website at www.altimmune.com.","length":497,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"2","style":"max-width:10%;width:10%;min-width:10%;vertical-align:top;","val":[{"type":"text","content":"Conference Call Details:","length":24,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"max-width:10%;width:10%;min-width:10%;vertical-align:top;","val":[{"type":"text","content":"Date:","length":5,"tagName":"p","attribs":{}}]},{"style":"max-width:90%;width:90%;min-width:90%;vertical-align:top;","val":[{"type":"text","content":"Thursday, June 26, 2025","length":23,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":"Time:","length":5,"tagName":"p","attr...

More updates from Altimmune, Inc.